2013至2021年欧洲幽门螺杆菌管理登记研究中含铋四联疗法使用、有效性和安全性的演变
基于欧洲幽门螺杆菌管理登记研究(Hp-EuReg)2013至2021年数据,49 690例患者中15 582例(31%)接受含铋四联疗法(BQT)。BQT使用率从2013年8.6%升至2021年39%。10天单胶囊BQT在各地理区域均达到90%以上治愈率,依从性、标准或高剂量PPI、14天疗程及一线使用与更高mITT有效性显著相关。
要点
- BQT使用率从2013年8.6%增至2021年39%,单胶囊BQT占43%。
- 10天单胶囊BQT在全部研究地理区域均达到90%以上治愈率。
- 依从性、标准或高剂量PPI、14天疗程及一线使用与更高mITT有效性显著相关。
核心结论
- 研究期间欧洲BQT使用显著增加,10天单胶囊BQT是最持续达到最佳有效性的方案。
研究设计与样本
- 基于欧洲幽门螺杆菌管理登记研究(Hp-EuReg)2013至2021年登记患者,纳入接受BQT者,分析处方方案、根除尝试次数、有效性、依从性和安全性,有效性采用改良意向治疗(mITT)评估,并进行时间趋势和多因素分析。
主要发现
- 49 690例患者中15 582例(31%)接受BQT,BQT使用率从2013年8.6%升至2021年39%。
- 单胶囊BQT(含铋、甲硝唑、四环素加PPI)是最常见治疗模式,占43%。
- 10天单胶囊BQT以及14天含四环素加甲硝唑或阿莫西林加克拉霉素或甲硝唑的BQT方案有效性超过90%。
- 仅单胶囊BQT在所有研究地理区域达到90%以上治愈率。
- 使用单胶囊BQT方案时,依从性、标准或高剂量PPI、14天处方及BQT作为一线治疗与更高mITT有效性显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. OBJECTIVE: To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg). DESIGN: Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success. RESULTS: Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT-containing bismuth, metronidazole and tetracycline-plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness. CONCLUSION: The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness. TRIAL REGISTRATION NUMBER: NCT02328131.
引用
- Olmedo L, Calvet X, Gené E, et al. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). Gut. 2024. PMID: 39461739. doi:10.1136/gutjnl-2024-332804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。